808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797628993081442304 |
|---|---|
| author | Patrick Hwu Apoorvi Chaudhri Ping Hua Xia Bu Michael A Davies Yunfei Wang Shao-Hsi Hung Ulrich Von Andrian Gordon Freeman Gregory A Lizee |
| author_facet | Patrick Hwu Apoorvi Chaudhri Ping Hua Xia Bu Michael A Davies Yunfei Wang Shao-Hsi Hung Ulrich Von Andrian Gordon Freeman Gregory A Lizee |
| author_sort | Patrick Hwu |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:48:04Z |
| format | Article |
| id | doaj.art-6e1a5c37223141a9b945039284ce6c08 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:48:04Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-6e1a5c37223141a9b945039284ce6c082023-11-13T22:50:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0808808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapyPatrick Hwu0Apoorvi Chaudhri1Ping Hua2Xia Bu3Michael A Davies4Yunfei Wang5Shao-Hsi Hung6Ulrich Von Andrian7Gordon Freeman8Gregory A Lizee91Moffitt Cancer Center, Tampa, FL, USA1Dana-Farber Cancer Institute, Boston, MA, USA1Dana-Farber Cancer Institute, Boston, MA, USA3Harvard Medical School, Boston, MA, USAThe University of Texas MD Anderson Cancer Center, Houston, TX, USA5H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAs4The University of Texas MD Anderson Cancer Center, Houston, TX, USA3Harvard Medical School, Boston, MA, USA1Dana-Farber Cancer Institute, Boston, MA, USA4The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| spellingShingle | Patrick Hwu Apoorvi Chaudhri Ping Hua Xia Bu Michael A Davies Yunfei Wang Shao-Hsi Hung Ulrich Von Andrian Gordon Freeman Gregory A Lizee 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy Journal for ImmunoTherapy of Cancer |
| title | 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy |
| title_full | 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy |
| title_fullStr | 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy |
| title_full_unstemmed | 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy |
| title_short | 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy |
| title_sort | 808 the cx3cl1 cx3cr1 chemokine axis can contribute to tumor immune evasion and blockade with a novel cx3cr1 monoclonal antibody enhances responses to anti pd 1 immunotherapy |
| work_keys_str_mv | AT patrickhwu 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT apoorvichaudhri 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT pinghua 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT xiabu 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT michaeladavies 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT yunfeiwang 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT shaohsihung 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT ulrichvonandrian 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT gordonfreeman 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy AT gregoryalizee 808thecx3cl1cx3cr1chemokineaxiscancontributetotumorimmuneevasionandblockadewithanovelcx3cr1monoclonalantibodyenhancesresponsestoantipd1immunotherapy |